钠-葡萄糖协同转运蛋白-2抑制剂在心血管疾病中的研究进展

SGLT-2 Inhibitors in Cardiovascular Diseases

中国目前的糖尿病患病率处在世界首位,而糖尿病常是伴随心血管疾病存在的,但传统降糖药除二甲双胍外对心血管几乎无益处,甚至还可能导致患心血管疾病的风险上升。近来受到广泛研究和关注的新型降糖药钠-葡萄糖协同转运蛋白-2抑制剂,能通过特异性地抑制肾脏重吸收葡萄糖来促进葡萄糖排泄,从而治疗2型糖尿病。此外,钠-葡萄糖协同转运蛋白-2抑制剂对于降低心力衰竭住院率和不良心血管事件的发病率和死亡率具有重要效用,现对钠-葡萄糖协同转运蛋白-2抑制剂在心血管疾病中的研究进展做一综述。

At present,the prevalence of diabetes mellitus is the highest in the world,and diabetes mellitus is often accompanied by cardiovascular diseases.However,traditional glucose-lowering drugs have no cardiovascular benefits except metformin and may even increase the risk of cardiovascular disease.Recently,a new type of glucose-lowering drug,sodium-glucose cotransporter 2 inhibitors(SGLT-2 inhibitors),has been widely concerned and studied.SGLT-2 inhibitors promote the excretion of glucose by specifically inhibiting the reabsorption of glucose by the kidneys so that they could treat type 2 diabetes.Meanwhile,studies find that SGLT-2 inhibitors also have significant effects for reducing adverse cardiovascular morbidity,mortality and the hospitalization of heart failure.Therefore,this paper will review the research progress of SGLT-2 inhibitors on cardiovascular diseases.